Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.400 Biomarker disease BEFREE ALT and ultrasound have mediocre accuracy in detecting steatosis in children with obesity. 30903305 2019
Entrez Id: 2308
Gene Symbol: FOXO1
FOXO1
0.080 AlteredExpression disease BEFREE Zfp125 is a Foxo1-inducible transcriptional repressor that causes lipid accumulation in the AML12 mouse hepatic cell line and liver steatosis in mice by reducing liver secretion of triglycerides and hepatocyte efflux of cholesterol. 29320745 2018
Entrez Id: 4547
Gene Symbol: MTTP
MTTP
0.400 Biomarker disease BEFREE Yet, the development of MTP inhibitors to lower plasma lipid concentrations has been hindered by adverse effects on hepatic steatosis. 24201112 2013
Entrez Id: 26291
Gene Symbol: FGF21
FGF21
0.400 Biomarker disease BEFREE With consumption of HFHS diet, FGF21 deficient mice (FGF21 KO) develop excess fatty liver within 16 weeks. 29753678 2018
Entrez Id: 948
Gene Symbol: CD36
CD36
0.100 Biomarker disease BEFREE Wild-type, constitutively activated AhR transgenic, AhR null and CD36/fatty acid translocase null mice were used to investigate the role of AhR in steatosis and the involvement of CD36 in the steatotic effect of AhR. 20303349 2010
Entrez Id: 196
Gene Symbol: AHR
AHR
0.080 Biomarker disease BEFREE Wild-type, constitutively activated AhR transgenic, AhR null and CD36/fatty acid translocase null mice were used to investigate the role of AhR in steatosis and the involvement of CD36 in the steatotic effect of AhR. 20303349 2010
Entrez Id: 79671
Gene Symbol: NLRX1
NLRX1
0.010 Biomarker disease BEFREE While mitochondrial content was equal, NLRX1 loss in hepatocytes leads to increased fatty acid oxidation and decreased steatosis. 29514047 2018
Entrez Id: 4306
Gene Symbol: NR3C2
NR3C2
0.030 Biomarker disease BEFREE While limited because of the small number of participants and the open-label design, this study provides data to suggest that mineralocorticoid receptor antagonism with eplerenone may not be an effective approach to treat hepatic steatosis in human immunodeficiency virus or the general population. 29509992 2018
Entrez Id: 7436
Gene Symbol: VLDLR
VLDLR
0.020 Biomarker disease BEFREE While HepG2 cells stably overexpressing VLDLR manifests increased intracellular triglyceride accumulation, VLDLR-deficient mice are protective against fatty liver and liver injury after chronic alcohol exposure. 24170703 2014
Entrez Id: 26027
Gene Symbol: ACOT11
ACOT11
0.010 AlteredExpression disease BEFREE When fed a high-fat diet, Them1 expression in liver promoted excess steatosis in the setting of reduced rates of fatty acid oxidation and preserved glycerolipid synthesis. 29208699 2018
Entrez Id: 1786
Gene Symbol: DNMT1
DNMT1
0.020 Biomarker disease BEFREE When fed a high-fat diet (HFD), similar to AIM-deficient (AIM<sup>-/-</sup>) mice, AIM-felinized mice exhibited enhanced triacylglycerol deposition in visceral adipocytes and hepatocytes, resulting in more prominent obesity and fatty liver than in wild-type mice. 30177770 2018
Entrez Id: 969
Gene Symbol: CD69
CD69
0.010 Biomarker disease BEFREE When fed a high-fat diet (HFD), similar to AIM-deficient (AIM<sup>-/-</sup>) mice, AIM-felinized mice exhibited enhanced triacylglycerol deposition in visceral adipocytes and hepatocytes, resulting in more prominent obesity and fatty liver than in wild-type mice. 30177770 2018
Entrez Id: 922
Gene Symbol: CD5L
CD5L
0.010 Biomarker disease BEFREE When fed a high-fat diet (HFD), similar to AIM-deficient (AIM<sup>-/-</sup>) mice, AIM-felinized mice exhibited enhanced triacylglycerol deposition in visceral adipocytes and hepatocytes, resulting in more prominent obesity and fatty liver than in wild-type mice. 30177770 2018
Entrez Id: 3091
Gene Symbol: HIF1A
HIF1A
0.060 Biomarker disease BEFREE When exposed to a choline-deficient diet (CDD) for 4 weeks, the loss of hepatic Hif-1α gene accelerated liver steatosis with enhanced triglyceride accumulation in the liver compared to wild-type (WT) livers. 30242180 2018
Entrez Id: 7124
Gene Symbol: TNF
TNF
0.400 AlteredExpression disease BEFREE When alcohol was consumed for 8 weeks with LGG treatment during the last 2 weeks, we demonstrated that the dose dependence of LGG granules can improve alcohol-induced liver injury through decreasing the levels of lipopolysaccharide and tumor necrosis factor-<i>α</i> in serum and prevent liver steatosis by suppressing triglyceride, free fatty acid, and malondialdehyde production in liver. 31747353 2020
Entrez Id: 5465
Gene Symbol: PPARA
PPARA
0.400 Biomarker disease BEFREE Western diet-fed PPARα-/- apoE2-KI mice displayed an aggravation of liver steatosis and inflammation compared with PPARα+/+ and PPARα+/- apoE2-KI mice, indicating a role of PPARα in liver protection. 21474829 2011
Entrez Id: 8878
Gene Symbol: SQSTM1
SQSTM1
0.050 Biomarker disease BEFREE Western blot showed that LC3 II/I was higher and p62 was lower on the early stage of steatosis while on the late stage both of them were higher, indicating that autophagic flux was activated on the early stage of steatosis, but blocked on the late stage. 29515134 2018
Entrez Id: 2965
Gene Symbol: GTF2H1
GTF2H1
0.040 Biomarker disease BEFREE Western blot showed that LC3 II/I was higher and p62 was lower on the early stage of steatosis while on the late stage both of them were higher, indicating that autophagic flux was activated on the early stage of steatosis, but blocked on the late stage. 29515134 2018
Entrez Id: 10657
Gene Symbol: KHDRBS1
KHDRBS1
0.040 Biomarker disease BEFREE Western blot showed that LC3 II/I was higher and p62 was lower on the early stage of steatosis while on the late stage both of them were higher, indicating that autophagic flux was activated on the early stage of steatosis, but blocked on the late stage. 29515134 2018
Entrez Id: 51164
Gene Symbol: DCTN4
DCTN4
0.040 Biomarker disease BEFREE Western blot showed that LC3 II/I was higher and p62 was lower on the early stage of steatosis while on the late stage both of them were higher, indicating that autophagic flux was activated on the early stage of steatosis, but blocked on the late stage. 29515134 2018
Entrez Id: 23636
Gene Symbol: NUP62
NUP62
0.040 Biomarker disease BEFREE Western blot showed that LC3 II/I was higher and p62 was lower on the early stage of steatosis while on the late stage both of them were higher, indicating that autophagic flux was activated on the early stage of steatosis, but blocked on the late stage. 29515134 2018
Entrez Id: 5987
Gene Symbol: TRIM27
TRIM27
0.010 Biomarker disease BEFREE Western blot and RFP-GFP-LC3 double fluorescence system indicated that celecoxib could ameliorate steatosis and restore autophagic flux in L02 cells treated with palmitate as well as SD rats fed with high-fat diet. 29515134 2018
Entrez Id: 2358
Gene Symbol: FPR2
FPR2
0.010 Biomarker disease BEFREE Western blot and RFP-GFP-LC3 double fluorescence system indicated that celecoxib could ameliorate steatosis and restore autophagic flux in L02 cells treated with palmitate as well as SD rats fed with high-fat diet. 29515134 2018
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.400 Biomarker disease BEFREE Weight loss interventions were statistically significantly associated with improvements in biomarkers, including alanine aminotransferase (-9.81 U/L; 95% CI, -13.12 to -6.50; I2 = 97%), histologically or radiologically measured liver steatosis (standardized mean difference: -1.48; 95% CI, -2.27 to -0.70; I2 = 94%), histologic NAFLD activity score (-0.92; 95% CI, -1.75 to -0.09; I2 = 95%), and presence of nonalcoholic steatohepatitis (OR, 0.14; 95% CI, 0.04-0.49; I2 = 0%). 31260026 2019
Entrez Id: 406991
Gene Symbol: MIR21
MIR21
0.040 AlteredExpression disease BEFREE We were able to show in vivo that reducing phospho-STAT3-miR-21 levels in C57/BL6 mice liver, by long-term treatment with metformin, protected mice from aging-dependent hepatic vesicular steatosis. 30206377 2018